Arcus Biosciences (NYSE:RCUS) Given Overweight Rating at Cantor Fitzgerald

Arcus Biosciences (NYSE:RCUS)‘s stock had its “overweight” rating reiterated by equities research analysts at Cantor Fitzgerald in a note issued to investors on Friday, Benzinga reports.

RCUS has been the topic of several other reports. Citigroup boosted their price objective on shares of Arcus Biosciences from $36.00 to $38.00 and gave the company a “buy” rating in a research note on Monday, June 3rd. Truist Financial dropped their price target on Arcus Biosciences from $50.00 to $44.00 and set a “buy” rating for the company in a research report on Monday, June 24th. Finally, Wedbush reissued an “outperform” rating and set a $30.00 price target on shares of Arcus Biosciences in a research report on Thursday, May 9th. One analyst has rated the stock with a hold rating and seven have assigned a buy rating to the company. According to MarketBeat.com, Arcus Biosciences presently has an average rating of “Moderate Buy” and a consensus price target of $39.75.

Arcus Biosciences Stock Performance

Shares of Arcus Biosciences stock traded down $0.32 on Friday, reaching $14.04. The company had a trading volume of 303,420 shares, compared to its average volume of 784,985. The firm has a market cap of $1.28 billion, a PE ratio of -4.54 and a beta of 0.90. The firm’s 50 day moving average price is $15.95 and its two-hundred day moving average price is $16.79. Arcus Biosciences has a 52-week low of $12.95 and a 52-week high of $25.47.

Arcus Biosciences (NYSE:RCUS) last posted its quarterly earnings results on Wednesday, May 8th. The company reported ($0.05) EPS for the quarter, topping the consensus estimate of ($0.97) by $0.92. The business had revenue of $145.00 million during the quarter, compared to the consensus estimate of $28.77 million. Arcus Biosciences had a negative net margin of 97.47% and a negative return on equity of 40.98%. The company’s quarterly revenue was up 480.0% compared to the same quarter last year. During the same quarter in the previous year, the firm posted ($1.09) earnings per share. As a group, sell-side analysts predict that Arcus Biosciences will post -2.61 EPS for the current year.

Institutional Investors Weigh In On Arcus Biosciences

Several large investors have recently added to or reduced their stakes in RCUS. GAMMA Investing LLC acquired a new stake in shares of Arcus Biosciences in the 4th quarter worth approximately $31,000. Public Employees Retirement System of Ohio acquired a new position in shares of Arcus Biosciences during the 3rd quarter valued at $36,000. Spartan Fund Management Inc. bought a new stake in shares of Arcus Biosciences in the 1st quarter worth $38,000. Headlands Technologies LLC acquired a new stake in shares of Arcus Biosciences in the first quarter valued at $59,000. Finally, Quest Partners LLC bought a new position in Arcus Biosciences during the fourth quarter valued at about $77,000. 92.89% of the stock is owned by institutional investors and hedge funds.

About Arcus Biosciences

Arcus Biosciences, Inc, a clinical-stage biopharmaceutical company, develops and commercializes cancer therapies in the United States. The company's pipeline products include Domvanalimab, an anti-TIGIT antibody, which is in Phase 2 and Phase 3 clinical trial; and AB308, an investigational anti-TIGIT monoclonal antibody, which is in Phase 1b clinical trial to study people with advanced solid and hematologic malignancies.